Regulatory Updates

Latest News

FDA Withdraws Approval of Pepaxto in Multiple Myeloma
FDA Withdraws Approval of Pepaxto in Multiple Myeloma

February 23rd 2024

Regulators indicated that the confirmatory study did not confirm Pepaxto’s clinical benefit and that there was no evidence of safety or efficacy.

FDA Grants Priority Review to Dupixent in COPD
FDA Grants Priority Review to Dupixent in COPD

February 23rd 2024

FDA Approves Biweekly Dosing of Tecvayli for Multiple Myeloma
FDA Approves Biweekly Dosing of Tecvayli for Multiple Myeloma

February 21st 2024

 LASZLO-stock.adobe.com
FDA Sets Review Date for Linvoseltamab for Advanced Multiple Myeloma

February 21st 2024

 iDoPixBox-stock.adobe.com
FDA Sets Date for First-in-Class Lung Cancer Therapy

February 19th 2024

Latest CME Events & Activities

More News

© 2024 MJH Life Sciences

All rights reserved.